Introduction: Cardiovascular Disease and Metabolic Risk Factors in Patients with Mental Illness

CNS Spectrums

Volumn 13, Issue S10, 2008, Pages 3-4

  Newcomer, John W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011454515     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900003084     Document Type: Article

References (14)

1. Kessler, RC, Chiu, WT, Demler, O, Merikangas, KR, Walters, EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):617–627.
2. Kessler, RC, Berglund, PA, Bruce, ML, et al. The prevalence and correlates of untreated serious mental illness. Health Serv Res. 2001; 36(6 pt 1):987–1007.
3. Colton, CW, Manderscheid, RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006; 3(2):A42.
4. Lopez, AD, Mathers, CD, Ezzati, M, Jamison, DT, Murray, CJL. Global Burden of Disease and Risk Factors, 2006. Disease Control Priorities Project and the International Bank for Reconstruction and Development, The World Bank, the World Health Organization, and the Fogarty International Center of the National Institutes of Health. Available at: http://files.dcp2.org/pdf/GBD/GBD.pdf. Accessed November 15, 2007.
5. Meyer, JM, Nasrallah, HA, eds. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Publishing; 2003.
6. Patel, VB, Robbins, MA, Topol, EJ. C-reactive protein: a ‘golden marker’ for inflammation and coronary artery disease. Cleve Clin J Med. 2001; 68(6):521–534.
7. Carr, LL. Summary of the role of statins in the treatment of dyslipidemia. J Am Osteopath Assoc. 2003; 103(7 suppl 3):S1–S3.
8. Lambert, TJ, Velakoulis, D, Pantelis, C. Medical comorbidity in schizophrenia. Med J Aust. 2003; 178 (suppl):S67–S70.
9. Marder, SR, Essock, SM, Miller, AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004; 161(8):1334–1349.
10. Newcomer, JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004; 26(12):1936–1946.
11. Newcomer, JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19(suppl 1):1–93.
12. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004; 65(2):267–272.
13. Cuffel, B, Martin, J, Joyce, A, Boccuzzi, S, Loebel, A. Lipid and glucose monitoring during atypical antipsychotic treatment: effect of 2004 ADA/APA consensus statement. Presented at: 159th Annual Meeting of the American Psychiatric Association; May 20–25, 2006; Toronto, Canada.
14. Parks, J, Svendsen, D, Singer, P, Foti, ME. Morbidity and mortality in people with serious mental illness. Thirteenth in a series of technical reports. Association of State Mental Health Program Directors (NASMHPD). Available at: http://www.nasmhpd.org/general_files/publications/med_directors_pubs/Technical%20Report%20on%20Morbidity%20and%20Mortaility%20-%20Final%2011–06.pdf. Accessed May 22, 2008.